These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24044187)

  • 21. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
    Chertow GM; Pupim LB; Block GA; Correa-Rotter R; Drueke TB; Floege J; Goodman WG; London GM; Mahaffey KW; Moe SM; Wheeler DC; Albizem M; Olson K; Klassen P; Parfrey P
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):898-905. PubMed ID: 17702710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with cinacalcet HCl.
    Ureña Torres P
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of cinacalcet in addition to standard of care in the UK.
    Ray JA; Valentine WJ; Palmer AJ
    Nephrol Dial Transplant; 2007 Nov; 22(11):3355-7; author reply 3357-8. PubMed ID: 17785347
    [No Abstract]   [Full Text] [Related]  

  • 26. Cinacalcet for the treatment of primary hyperparathyroidism.
    Dillon ML; Frazee LA
    Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
    Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
    J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical issues regarding cinacalcet hydrochloride in Japan.
    Yokoyama K
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S12-4. PubMed ID: 19765252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
    Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of calcimimetics in surgery of secondary hyperparathyroidism.
    Ruiz J; Ríos A; Rodríguez JM; Llorente S; Hernández AM; Parrilla P
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):59-61. PubMed ID: 28440773
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report.
    Fusaro M; D'Angelo A; Naso A; Frigo AC; Miozzo D; Gallieni M; Calò LA
    Ren Fail; 2011; 33(7):732-5. PubMed ID: 21671845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
    Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.
    Dorsch O
    Nephrol Dial Transplant; 2007 Feb; 22(2):637-40. PubMed ID: 17095580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.